Thursday, March 3, 2011
The European Medicines Agency gave Vical Inc., of San Diego, scientific advice pertaining to its endpoints for a Phase III trial of TransVax, a cytomegalovirus vaccine. The EMA said that a CMV disease endpoint was not practical, because of the low incidence of CMV disease and the small size of the target population. Vical is also working on plans for a pivotal Phase III trial with the FDA.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.